Equities Analysts Offer Predictions for Accuray Q2 Earnings

Accuray Incorporated (NASDAQ:ARAY) – Roth Capital decreased their Q2 2025 earnings per share (EPS) estimates for Accuray in a research note issued to investors on Tuesday, November 19th. Roth Capital analyst J. Wittes now anticipates that the medical equipment provider will post earnings per share of $0.00 for the quarter, down from their prior forecast of $0.01. The consensus estimate for Accuray’s current full-year earnings is $0.01 per share. Roth Capital also issued estimates for Accuray’s Q4 2025 earnings at $0.05 EPS.

Separately, StockNews.com lowered Accuray from a “buy” rating to a “hold” rating in a research note on Friday, November 15th.

Accuray Price Performance

NASDAQ:ARAY opened at $1.89 on Thursday. The firm has a market capitalization of $189.57 million, a price-to-earnings ratio of -10.94 and a beta of 1.40. Accuray has a 52-week low of $1.40 and a 52-week high of $3.05. The stock has a fifty day moving average of $1.85 and a 200 day moving average of $1.83. The company has a debt-to-equity ratio of 3.59, a quick ratio of 0.87 and a current ratio of 1.63.

Accuray (NASDAQ:ARAY) last posted its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported ($0.04) EPS for the quarter, hitting analysts’ consensus estimates of ($0.04). The firm had revenue of $101.55 million during the quarter, compared to analyst estimates of $98.10 million. Accuray had a negative return on equity of 36.93% and a negative net margin of 3.72%. During the same period last year, the company earned ($0.03) earnings per share.

Institutional Investors Weigh In On Accuray

A number of large investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC raised its position in Accuray by 0.3% during the second quarter. Renaissance Technologies LLC now owns 2,812,184 shares of the medical equipment provider’s stock valued at $5,118,000 after purchasing an additional 7,500 shares in the last quarter. Foundry Partners LLC raised its position in Accuray by 51.3% during the third quarter. Foundry Partners LLC now owns 2,187,160 shares of the medical equipment provider’s stock valued at $3,937,000 after purchasing an additional 741,900 shares in the last quarter. Geode Capital Management LLC raised its position in Accuray by 2.1% during the third quarter. Geode Capital Management LLC now owns 2,179,396 shares of the medical equipment provider’s stock valued at $3,924,000 after purchasing an additional 45,548 shares in the last quarter. State Street Corp raised its position in Accuray by 3.8% during the third quarter. State Street Corp now owns 1,894,287 shares of the medical equipment provider’s stock valued at $3,410,000 after purchasing an additional 70,008 shares in the last quarter. Finally, FMR LLC raised its position in Accuray by 27.2% during the third quarter. FMR LLC now owns 582,591 shares of the medical equipment provider’s stock valued at $1,049,000 after purchasing an additional 124,459 shares in the last quarter. Hedge funds and other institutional investors own 64.08% of the company’s stock.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.